Skip to main content

Illumina company profile

  • ILMN · Nasdaq
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$198.26−4.22%Close 16 Nov 2026 · Market value $30.43B

About Illumina

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.

Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies.

From Wikipedia, shared under CC BY-SA.

Company facts

TickerILMN · Nasdaq
SectorInstruments
IndustryLife Sciences Tools & Services
IndexS&P 500
Fiscal year ends28 December
Reporting currencyUSD
CIK1110803

Officers and directors

NameRoleShares ownedLatest Form 4
Keith MeisterDirector4.2M · 2.8%Open-market sale, 11 Nov 2026
Jacob ThaysenChief Executive Officer · Director40.3K · < 1%Shares withheld for tax, 5 Oct 2026
Robert EpsteinDirector22.1K · < 1%Grant or award, 21 May 2025
Frances ArnoldDirector20.9K · < 1%Grant or award, 21 May 2025
Philip SchillerDirector20.1K · < 1%Grant or award, 21 May 2026
Gary GuthartDirector16.4K · < 1%Grant or award, 21 May 2025
Caroline DorsaDirector15.2K · < 1%Grant or award, 21 May 2026
Susan SiegelDirector14.5K · < 1%Grant or award, 21 May 2026
Kevin PegelsChief of Global Operations13.1K · < 1%Shares withheld for tax, 5 Nov 2026
Ankur DhingraSVP, Chief Financial Officer13.1K · < 1%Grant or award, 5 Mar 2026
Scott GottliebDirector12.7K · < 1%Grant or award, 21 May 2026
Scott UllemDirector8.6K · < 1%Grant or award, 30 Sep 2026
Anna RichoDirector6.5K · < 1%Grant or award, 21 May 2026
Everett CunninghamSVP, Chief Commercial Officer4.7K · < 1%Shares withheld for tax, 5 Jul 2025
David KingDirector0 · < 1%Grant or award, 21 May 2026
Ericksen Scott DVP, Chief Accounting Officer—Sale under a 10b5-1 plan, 10 Nov 2026
Barnard StevenSVP, Chief Technology Officer—Shares withheld for tax, 5 Nov 2026
Leckman PatriciaSVP, Chief People Officer—Shares withheld for tax, 5 Nov 2026
Coletti Julie AnnChief Legal Officer—Grant or award, 8 Sep 2026
Wedel Christensen JakobSVP, Strategy/Corp Development—Sale under a 10b5-1 plan, 18 Aug 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

ILMN in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.